The longevity pharmacology world has a short list of drugs that have actually, demonstrably, extended lifespan in a rigorous scientific setting. Rapamycin is at the top. Metformin gets a lot of airtime. And then there's canagliflozin — a diabetes drug that most people outside of cardiology or nephrology circles have never heard of, quietly sitting on some of the most compelling lifespan data in the entire field.
You've probably seen SGLT2 inhibitors mentioned in the context of heart failure or Type 2 diabetes. That's where they started. But over the last several years, the research has taken a sharp turn toward something bigger: whether these drugs, and canagliflozin in particular, could be a legitimate longevity tool for people who don't have diabetes at all. The short answer is: possibly, yes. The long answer requires some nuance — and some honest accounting of what we know versus what we're extrapolating.
This article breaks down what canagliflozin actually does, why its lifespan data is so unusually strong, what the evidence says about its longevity-relevant benefits, and who might actually be a good candidate for it. No hype. Just the research, clearly translated.
What Is Canagliflozin (Really)?
Canagliflozin is an SGLT2 inhibitor — a class of drugs that works by blocking a protein in your kidneys called sodium-glucose cotransporter 2. That protein's job is to reabsorb glucose back into your bloodstream after your kidneys filter it out. Block it, and glucose gets excreted in your urine instead of recycling through your system. Your blood sugar drops. Your insulin load drops. And a cascade of downstream metabolic effects follows.
It was approved by the FDA in 2013 under the brand name Invokana, originally for Type 2 diabetes management. But here's the thing: the mechanism doesn't care whether you have diabetes. The metabolic pathways canagliflozin touches — glucose regulation, insulin sensitivity, cellular energy sensing, cardiovascular stress — are relevant to aging biology regardless of your blood sugar levels.
Think of it this way: if your body's glucose handling is like a thermostat that's been slightly miscalibrated for years, canagliflozin doesn't just fix the thermostat for people whose house is on fire. It recalibrates the system more broadly, and that recalibration turns out to have effects that matter for how you age.
The ITP Data: Why This Is Different
Ready for some science that won't put you to sleep? Because this part actually matters.
The Interventions Testing Program (ITP) is run by the National Institute on Aging and is, essentially, the gold standard for testing whether a drug actually extends lifespan in mammals. The bar is high: drugs are tested simultaneously across three independent research sites, in genetically diverse mice, under rigorous conditions. Most things fail. Rapamycin passed. Acarbose passed. And canagliflozin passed — with some striking specificity.
In the ITP study published in 2020, canagliflozin extended median lifespan in male mice by 14%, with a significant effect on maximum lifespan as well. Females showed a much smaller, statistically non-significant effect. The male-specific finding was strong enough that researchers took it seriously as a signal, not noise.
Why males? The leading hypothesis involves something called the "glucose excretion effect" and how it interacts with baseline metabolic state. Male mice in ITP studies tend to have higher baseline glucose and insulin levels than females, so the drug may have more metabolic territory to correct. There's also emerging work suggesting that SGLT2 inhibitors may mimic aspects of caloric restriction more effectively in male physiology — though that's still being worked out.
What makes the canagliflozin ITP result particularly notable is that it was the largest lifespan extension seen in male mice in any ITP trial to date at the time of publication. That's a sentence worth sitting with. The entire field of longevity pharmacology, and one of the biggest effects on record came from a drug your cardiologist has been prescribing for heart failure.
How Canagliflozin Works for Longevity: The Mechanisms
The glucose-excretion piece is the easy explanation, but it's not the whole story. Here's what canagliflozin appears to be doing at the cellular level that makes it interesting for longevity specifically:
AMPK Activation and mTOR Suppression
When canagliflozin forces glucose out through your kidneys, your cells perceive a mild energy deficit. That triggers activation of AMPK (AMP-activated protein kinase) — your cells' fuel gauge, essentially. When AMPK goes up, it tends to suppress mTOR signaling (the cellular growth pathway that, when chronically overactivated, is associated with accelerated aging). This is the same mTOR-suppression axis that rapamycin targets directly. Canagliflozin gets there via a different route.
Caloric Restriction Mimicry
Losing glucose in your urine means your body is functionally operating on slightly fewer usable calories, even if you're eating the same amount. This creates a metabolic state that resembles, in some ways, mild caloric restriction — one of the most reliably life-extending interventions known in animal models. You're not starving. Your cells just think they're working a little harder for fuel, and they respond accordingly.
Cardiovascular and Renal Protection
This is where the human data gets robust. The CREDENCE trial and the CANVAS program showed significant reductions in cardiovascular death, heart failure hospitalizations, and kidney disease progression in people with Type 2 diabetes. The EMPA-REG trial for empagliflozin (a close cousin in the same drug class) showed similar results. Across the class, SGLT2 inhibitors appear to reduce cardiac preload and afterload, lower blood pressure modestly, and reduce inflammation in ways that matter for long-term cardiovascular aging.
Mitochondrial Function and Cellular Senescence
More recent mechanistic work suggests SGLT2 inhibitors may reduce the accumulation of senescent cells (the "zombie cells" that stop dividing but refuse to die and cause inflammation in surrounding tissue) and support mitochondrial function. These are two of the core biological processes implicated in aging. The research here is earlier-stage than the cardiovascular data, but it's directionally consistent with the lifespan findings.
What the Evidence Actually Shows: Benefits Worth Knowing
- Lifespan extension in male mice: 14% median lifespan increase in ITP testing — the strongest signal in that program's history for male mice. Mechanistically plausible. Not yet proven in humans for this indication.
- Cardiovascular mortality reduction: In the CANVAS program (Neal et al., 2017), canagliflozin reduced major adverse cardiovascular events by 14% versus placebo in people with Type 2 diabetes and high CV risk. This is hard endpoint data from large human trials.
- Heart failure hospitalization: Canagliflozin reduced the risk of hospitalization for heart failure by 33% in the CANVAS program — an effect size that made cardiologists take serious notice.
- Kidney disease progression: The CREDENCE trial showed a 30% relative risk reduction in the primary composite kidney outcome. Kidney function decline is a major driver of overall health deterioration in aging.
- Metabolic markers: Across studies, canagliflozin produces modest but consistent reductions in HbA1c, fasting glucose, blood pressure, and body weight. Even in non-diabetic populations, improved glucose regulation and reduced insulin burden are relevant to long-term metabolic aging.
The honest framing: the cardiovascular and renal benefits are proven in people with existing disease. The longevity application — using this drug in healthy, non-diabetic people specifically to extend healthspan — is a reasonable hypothesis supported by strong mechanistic and animal data. But we don't yet have a randomized controlled trial in healthy humans showing it extends lifespan. That study doesn't exist yet for any longevity drug.
The Reality Check
You are not a mouse. That needs to be said clearly. The ITP data is compelling, but rodent lifespan studies have a long history of not translating cleanly to humans. The 14% median lifespan extension in male mice is genuinely exciting — and it should be treated as a strong hypothesis generator, not proof of effect in humans.
The sex-specific finding also deserves scrutiny. The female mouse data showed minimal effect. Whether this maps to humans in the same way isn't known. Hormonal differences between sexes, baseline metabolic profiles, and the specific mechanisms involved may or may not align with the mouse findings.
There's also a dosing question. The ITP study used a dose of 180 mg/kg of food, which translates to roughly 15–20 mg/day in a human equivalent dose — within the clinically approved range for diabetes (100–300 mg/day), but the extrapolation isn't clean. Optimal dosing for longevity purposes in non-diabetic humans is genuinely unknown.
The internet wants this to be the next rapamycin. The research is more nuanced. What it actually is: a drug with a strong, reproducible mechanistic basis for longevity effects, excellent human safety data from its approved indications, and the most compelling mammalian lifespan data in its drug class. That's not nothing. It's actually a lot. But it's not a guaranteed outcome.
Who Is Canagliflozin Actually Right For?
The profile of someone for whom canagliflozin makes the most sense as a longevity intervention looks something like this:
- Age 40+, particularly men, given the sex-specific ITP data (though the mechanistic benefits are relevant to women too)
- Signs of metabolic drift: fasting glucose creeping upward, elevated HbA1c (even pre-diabetic range), insulin resistance on labs, or difficulty maintaining weight despite reasonable diet and exercise
- Cardiovascular risk factors: family history, elevated blood pressure, borderline lipids, or early markers of cardiovascular aging
- Interest in longevity pharmacology and a willingness to engage with ongoing monitoring — because this isn't a supplement you take and forget about
- No history of recurrent urinary tract infections, genital yeast infections, or significant kidney impairment (these are meaningful contraindications)
- Already optimizing the basics: sleep, exercise, nutrition. Canagliflozin is not a substitute for metabolic health fundamentals — it's a pharmacological layer on top of them
If your metabolic labs are pristine and your cardiovascular risk is genuinely low, the case is weaker — not nonexistent, but the signal-to-noise ratio is lower. If you're in the metabolic gray zone that describes a significant portion of adults over 40, the case gets more interesting.
Risks and Side Effects: What You Actually Need to Know
SGLT2 inhibitors have a real side effect profile, and it's worth knowing it clearly:
- Genital mycotic infections (yeast infections): The most common side effect, because glucose in the urine creates a favorable environment for yeast. More common in women than men.
- Urinary tract infections: Modestly increased risk. Hydration helps. Worth monitoring.
- DKA risk (diabetic ketoacidosis): Rare in non-diabetic users, but real. The risk increases significantly if you're combining this with extended fasting, very low-carb diets, or are under significant physiological stress (surgery, illness). This is why supervision matters.
- Volume depletion and blood pressure: The glucose and sodium excretion can cause mild dehydration and a blood pressure drop. Usually manageable, but relevant if you're already on antihypertensives or have low baseline BP.
- Lower limb amputations: A signal seen in the original CANVAS data, more pronounced at higher cardiovascular risk. The mechanism isn't fully understood. This finding is real, though the absolute risk increase was small and subsequent analyses have been more reassuring.
- Bone fracture risk: Some signal in CANVAS. Not seen consistently across the class.
None of these make canagliflozin a dangerous drug — millions of people take it daily. But they make it a drug that warrants medical supervision, not a DIY experiment.
How to Get Started: The Healthspan Approach
If canagliflozin sounds like something worth exploring, the right starting point isn't a random online pharmacy. It's a clinical protocol that begins with your actual metabolic picture.
Healthspan's Canagliflozin protocol is built around that principle: start with labs, not assumptions. Before any prescription is written, you'll work with a Healthspan clinician who reviews your metabolic markers, cardiovascular risk profile, kidney function, and overall health context. The protocol includes baseline and follow-up lab monitoring, individualized dosing, and ongoing clinical oversight — because the goal isn't just to start a drug, it's to make sure it's actually doing what you want it to do and not creating problems you didn't see coming.
If you're not sure where your metabolic health actually stands, the Metabolic Pro Panel is a logical first step — it gives you the baseline data (glucose, insulin, HbA1c, lipids, kidney markers, and more) that any sensible canagliflozin conversation should start with. And for those interested in a broader longevity pharmacology stack, the SGLT2 Protocol integrates canagliflozin with clinical context specifically designed for longevity optimization rather than disease treatment.
The difference between taking this drug thoughtfully and taking it recklessly is clinical supervision. If you want to explore whether canagliflozin makes sense for your biology, start with a consultation.
Frequently Asked Questions
Does canagliflozin extend lifespan in humans?
Not proven yet in humans for longevity specifically. The ITP data showing 14% median lifespan extension in male mice is the strongest mammalian signal in its class, but we don't have a randomized longevity trial in healthy humans. The cardiovascular and renal benefits in human trials with high-risk populations are well-established. The longevity hypothesis in healthy people is biologically plausible and actively researched.
Can you take canagliflozin if you don't have diabetes?
Yes, though it's prescribed off-label for non-diabetic longevity use. The drug is FDA-approved for Type 2 diabetes, heart failure, and chronic kidney disease, but the mechanisms it targets are relevant regardless of diabetic status. Off-label use requires a prescribing clinician and appropriate monitoring. Canagliflozin is not a supplement you can buy without a prescription.
How does canagliflozin compare to metformin for longevity?
Metformin has more extensive human data and longer use history in the longevity context, but the ITP lifespan data for canagliflozin in males was stronger than what was seen for metformin in that program. They target overlapping but distinct pathways (both activate AMPK; metformin also inhibits complex I of the mitochondrial electron transport chain). Many longevity clinicians consider them complementary rather than competing.
Why did canagliflozin only extend lifespan in male mice, not female?
The leading hypothesis is that male mice in ITP studies have higher baseline glucose and insulin levels, giving the drug more metabolic dysregulation to correct. There may also be hormonal factors affecting how the drug interacts with glucose metabolism. Whether this sex difference translates to humans is unknown. The mechanistic benefits of SGLT2 inhibition are not inherently sex-specific, so female applicability remains an open question.
What are the most common side effects of canagliflozin?
Genital yeast infections and urinary tract infections are the most common, driven by glucose in the urine. Mild blood pressure reduction and dehydration can occur. There's a rare but real risk of diabetic ketoacidosis, particularly with extended fasting or very low-carb diets. A lower limb amputation signal was seen in one large trial; absolute risk was small but real. Medical supervision and regular monitoring address most of these concerns proactively.
What dose of canagliflozin is used for longevity?
There's no established longevity-specific dose, because the longevity indication hasn't been formally studied in humans. The ITP mouse data used doses that translate roughly to the lower end of the clinically approved range. Most longevity-focused clinicians start at 100 mg/day and adjust based on labs and clinical response. The right dose for your biology is something a clinician determines, not something to self-prescribe.
Can canagliflozin be combined with rapamycin or other longevity drugs?
Combination protocols are increasingly common in longevity medicine, and canagliflozin's AMPK-activating mechanism is complementary to rapamycin's mTOR-inhibiting action. The two drugs target aging biology through different but synergistic pathways. Combining them requires clinical oversight to manage side effects and monitor for interactions. Healthspan's Longevity Optimization protocol is designed for exactly this kind of multi-agent approach.